HOMSC-200 is under clinical development by Cytora and currently in Phase I for Diabetic Foot Ulcers. According to GlobalData, Phase I drugs for Diabetic Foot Ulcers does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the HOMSC-200 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HOMSC-200 overview
The drug candidate is under development for the treatment of diabetic foot ulcers. It comprises of allogeneic human oral mucosa stem cells (hOMSCs) and is developed based on hOMSC technology platform. It is administered through oral route.
Cytora overview
Cytora is a biotechnology research company which focuses to develop novel stem cell therapies technology to treat wounds and foot ulcers which occur as an side effect of diabetes. Cytora is headquartered in Ramat Gan, Israel.
For a complete picture of HOMSC-200’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
